Your browser doesn't support javascript.
loading
Evaluation and Management Outcomes and Burdens in Patients with Refractory Chronic Cough Referred for Behavioral Cough Suppression Therapy.
Slovarp, Laurie J; Jetté, Marie E; Gillespie, Amanda I; Reynolds, Jane E; Barkmeier-Kraemer, Julie M.
  • Slovarp LJ; School of Speech, Language, Hearing, & Occupational Sciences, University of Montana, 32 Campus Dr., Missoula, MT, USA. laurie.slovarp@umontana.edu.
  • Jetté ME; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
  • Gillespie AI; Department of Otolaryngology, Emory University School of Medicine, Atlanta, GA, USA.
  • Reynolds JE; School of Speech, Language, Hearing, & Occupational Sciences, University of Montana, 32 Campus Dr., Missoula, MT, USA.
  • Barkmeier-Kraemer JM; Department of Otolaryngology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Lung ; 199(3): 263-271, 2021 06.
Article en En | MEDLINE | ID: mdl-33821355
ABSTRACT

PURPOSE:

The purpose of this study was to investigate the typical symptoms and medical management characteristics of adult patients with refractory chronic cough (RCC) who are referred to speech-language pathology (SLP) for behavioral cough suppression therapy (BCST) in order to estimate cost-effectiveness and efficiency of current practice patterns for this population.

METHODS:

One hundred sixty-four (164) patients with RCC referred for BCST were surveyed. Patients completed an initial survey at BCST onset related to symptom pattern and prior treatment, including the Leicester Cough Questionnaire (LCQ). Every four to six weeks patients completed follow-up surveys to assess their response to BCST.

RESULTS:

Mean age was 58 years (83.5% women). The majority of patients reported their cough began two or more years prior to BCST. Approximately half (49%) reported seeing four or more physicians (including primary care physicians) and being prescribed four or more medications (57%) prior to BCST. Medications targeting post-nasal drip (72%), reflux (70%), asthma (56%), and allergies (56%) were most commonly prescribed. BCST resulted in a clinically significant improvement in 70.1% of participants. The mean change in LCQ for those who improved with BCST was 6.61. Over half (58%) reported they were quite satisfied to completely satisfied with their treatment response. The average time from enrollment to study completion was 64 days.

CONCLUSION:

The results of this study suggest early intervention with BCST may be a cost-effective and efficient option for patients with RCC.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Terapia Cognitivo-Conductual / Encuestas y Cuestionarios / Costo de Enfermedad / Manejo de la Enfermedad / Tos Tipo de estudio: Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Terapia Cognitivo-Conductual / Encuestas y Cuestionarios / Costo de Enfermedad / Manejo de la Enfermedad / Tos Tipo de estudio: Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article